Skip to main content
Premium Trial:

Request an Annual Quote

Response Genetics Extends Test Agreement with GSK

NEW YORK (GenomeWeb News) — Response Genetics said Friday that it has extended its agreement to provide genetic testing services to GlaxoSmithKline, which will use the services in conjunction with developing cancer treatments.
 
The companies agreed to extend their current master service agreement for two years, and GSK agreed to pay Response Genetics $1.3 million up front.
 
Response Genetics owns a panel of molecular markers for use in its PCR-based genetic tests, including ResponseDX: Lung and ResponseDX: Colon.